91³ÉÈ˰涶Òô

About this webinar:

The Tina Trial is a world-first phase 3 trial of mirtazapine for methamphetamine use disorder. The trial was funded by the MRFF and was completed in May 2025. The trial involved recruiting participants from across six sites in Australia (Wollongong, Geelong, Brisbane, Perth, Townsville and Adelaide) using a centralised trial platform and electronic data capture. 344 participants were randomised to the study intervention. Follow-up over the 12-week intervention period was 89%. The trial captured a broad cohort of people who use methamphetamine, with around half not having previously received specialist drug treatment for their methamphetamine use. This presentation will reflect on the process of conducting the trial, and the experiences of the research team, with a view to informing the conduct of future trials and other intervention research in this area.

About the speaker:

Professor Rebecca McKetin (BSc(Psychol)Hons. PhD) leads a program of research into stimulant use epidemiology and interventions at the National Drug and Alcohol Research Centre, UNSW. Her vision is to improve the availability of evidence-based interventions to reduce the harm from methamphetamine use in Australia. Her current research involves evaluating pharmacological interventions for methamphetamine use, developing and evaluating online psychological interventions for stimulant use, and adapting of evidence-based behavioural therapies, such as contingency management, to the Australian context. Her past work has been pivotal in quantifying the mental and physical health risks associated with methamphetamine use. Rebecca is the coordinating principal investigator on the recently completed Tina Trial, a Phase 3 randomised placebo-controlled double-blind trial of mirtazapine for methamphetamine use disorder.